NCT00675207View on ClinicalTrials.gov

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Primary Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

Brimonidine purite 0.15%

A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.

DRUG

Dorzolamide 2%

A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.

DRUG

Brinzolamide 1%

A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.

Trial Locations (1)

60026

Northwestern Ophthalmic Institute S.C., Glenview

All Listed Sponsors
collaborator

Research to Prevent Blindness

OTHER

lead

Northwestern Ophthalmic Institute S.C.

OTHER

NCT00675207 - Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs | Biotech Hunter | Biotech Hunter